Mainz Biomed signed a License and Option Agreement with Liquid Biosciences to access a cutting-edge mRNA biomarker platform for non-invasive, blood-based pancreatic cancer screening.
Read MoreGuido Baechler
PancAlert: Mainz Biomed Launches Feasibility Study for Pancreatic Cancer Blood Test
PancAlert feasibility study is designed to validate compelling results from a discovery phase completed earlier this year in partnership with Liquid Biosciences
Read More
Mainz Biomed Targets Cancer Prevention with mRNA-Powered eAArly DETECT 2 Study
Mainz Biomed innovative CRC screening approach combines five proprietary mRNA biomarkers with advanced AI and diagnostic tools.
Read More